Epidemiology & Real-World Evidence Strategy Leader

Neurocrine Biosciences; San Diego (CA); On-site; USD 230,000 - 314,000; Full time

Benefits offered by this job

Competitive base salary

Annual bonus target 35%

Equity long-term incentives

Retirement plan with company match

Job summary

Neurocrine Biosciences is seeking a senior leader to define and execute enterprise epidemiology and real‑world evidence (RWE) strategies across R&D, Medical, Market Access and Analytics. You will partner with regulatory, HTA and payer teams to drive high‑quality evidence generation for submissions and lifecycle management.

You will lead and develop Directors, Managers, and senior scientists, oversee budgets, and ensure rigorous methods across programs, collaborating with external partners and

Qualifications

• Master's Degree AND 12+ years of relevant experience OR PhD, PharmD, or MD in Epidemiology, Public Health, or a related field AND 10+ years of pharmaceutical or biotech experience in epidemiology and/or real-world evidence.

Responsibilities

• Define and lead enterprise-wide epidemiology and RWE strategy across R&D, Medical, Market Access, and Analytics.
• Translate enterprise RWE strategy into portfolio- and therapeutic-area level evidence plans.
• Provide strategic oversight for regulatory submissions, HTAs, reimbursement decisions, and value demonstration.

Skills

Epidemiology

Real‑world evidence

Leadership

Strategic planning

Regulatory knowledge

Education

Master's degree in Epidemiology/Public Health

PhD/PharmD/MD in related field

Job description

Neurocrine Biosciences is seeking a senior leader to define and execute enterprise epidemiology and real‑world evidence (RWE) strategies across R&D, Medical, Market Access and Analytics. You will partner with regulatory, HTA and payer teams to drive high‑quality evidence generation for submissions and lifecycle management.

You will lead and develop Directors, Managers, and senior scientists, oversee budgets, and ensure rigorous methods across programs, collaborating with external partners and